ReviewCardiovascular & hematological disorders drug targets2026

Zerlasiran for Lipoprotein(a) Reduction: Mechanisms, Evidence, and Future Directions.

Mohanad Elchouemi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.